Logo image
Interferon-alpha, immune activation and immune dysfunction in treated HIV infection
Journal article   Open access   Peer reviewed

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

L. Cha, C.M. Berry, D. Nolan, A. Castley, S. Fernandez and M.A. French
Clinical & Translational Immunology, Vol.3(2), e10
2014
pdf
treated_HIV_infection.pdfDownloadView
Published (Version of Record)CC BY V4.0 Open Access
url
Link to Published Version *Subscription may be requiredView

Abstract

Type I interferons (IFNs) exert anti-viral effects through the induction of numerous IFN-stimulated genes and an immunomodulatory effect on innate and adaptive immune responses. This is beneficial in controlling virus infections but prolonged IFN-α activity in persistent virus infections, such as HIV infection, may contribute to immune activation and have a detrimental effect on the function of monocytes and T and B lymphocytes. Activation of monocytes, associated with increased IFN-α activity, contributes to atherosclerotic vascular disease, brain disease and other ‘age-related diseases’ in HIV patients treated with long-term antiretroviral therapy (ART). In HIV patients receiving ART, the anti-viral effects of IFN-α therapy have the potential to contribute to eradication of HIV infection while IFN-α inhibitor therapy is under investigation for the treatment of immune activation. The management of HIV patients receiving ART will be improved by understanding more about the opposing effects of IFN-α on HIV infection and disease and by developing methods to assess IFN-α activity in clinical practice.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

141 File views/ downloads
94 Record Views
Logo image